Advanced Biomed Inc. (NASDAQ:ADVB) Shares Shorted: Short Interest Down 48.4% in October

Advanced Biomed Inc. (NASDAQ:ADVB) saw a large drop in short interest in the month of October. As of October 15th, there was short interest totaling 9,747 shares, a drop of 48.4% from the September 30th total of 18,897 shares. Currently, 0.8% of the company’s shares are sold short. Based on an average daily volume of 16,412 shares, the days-to-cover ratio is presently 0.6 days.

Advanced Biomed Stock Down 12.9%

Shares of Advanced Biomed stock traded down $0.34 during trading on Friday, reaching $2.30. 21,780 shares of the stock were exchanged, compared to its average volume of 38,334. The firm has a market cap of $3.79 million, a price-to-earnings ratio of 0.48 and a beta of 0.01. Advanced Biomed has a 1 year low of $2.25 and a 1 year high of $24.23. The stock’s fifty day moving average is $6.52 and its 200 day moving average is $5.91.

Advanced Biomed (NASDAQ:ADVB) last released its quarterly earnings results on Tuesday, October 13th. The company reported $0.44 EPS for the quarter.

Analyst Upgrades and Downgrades

ADVB has been the topic of a number of recent research reports. Wall Street Zen cut Advanced Biomed from a “hold” rating to a “sell” rating in a research note on Saturday, October 17th. Weiss Ratings lowered Advanced Biomed from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, October 8th. One research analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, the company presently has an average rating of “Sell”.

Advanced Biomed Company Profile

Our Mission We are committed to the application research of integrating semiconductor technology and biotechnology. Through the enrichment, capture, and identification of circulating tumor cells and related tumor marker cells in the field of liquid biopsy, we aim to provide cancer patients with rapid and affordable assay products and services. These services include early screening and detection, diagnosis and staging, treatment selection, and patient outcome interventions for cancer. We are a holding company incorporated in the State of Nevada.